Resistance to immune checkpoint inhibitors remains a significant challenge in the treatment of cancer.
Emerging evidence suggests that metabolic reprogramming plays a crucial role in tumor metabolism and progression.
Our study strived to investigate the role and underlying mechanisms of the glutamate transporter SLC1A6 in resistance to immunotherapy of cancer.
